Methylation status of the FHIT gene in the transformed human mesenchymal F6 stem cell line

Xu,Xue‑Jing; Gao,Shuo; Wang,Mei; Qian,Hui; Gu,Guang‑Yu; Zhang,Kui; Xu,Wen‑Rong

doi:10.3892/ol.2015.3092

Methylation status of the FHIT gene in the transformed human mesenchymal F6 stem cell line

Authors:
- Xue‑Jing Xu
- Shuo Gao
- Mei Wang
- Hui Qian
- Guang‑Yu Gu
- Kui Zhang
- Wen‑Rong Xu
View Affiliations

Affiliations: Department of Laboratory Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, P.R. China, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China
Published online on: April 1, 2015 https://doi.org/10.3892/ol.2015.3092
Pages: 2661-2666

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The fragile histidine triad (FHIT) gene is known to be a tumor suppressor gene and the abnormal methylation of FHIT has been identified in leukemia and several solid tumors. The transformation of the tumor F6 cell line from human fetal mesenchymal stem cells (FMSCs) was first reported in a previous study that also identified the presence of a population of cancer stem cells in the F6 cell line. However, the existence of the epigenetic changes during the transformation process have yet to be elucidated. To confirm the role of the FHIT gene in the transformation process of FMSC, the expression level and methylation status of the FHIT gene was examined in F6 tumor cells and FMSCs. Additionally, the alteration in cell morphology, the cell cycle and apoptosis in F6 cells following 5‑Aza‑CdR treatment was assessed. It was found that the FHIT gene was expressed in FMSCs, but not in F6 cells. The methylation‑specific PCR results demonstrated that the promoter methylation of FHIT genes existed in the F6 cell line. Subsequent to treatment with 5‑Aza‑CdR the expression of FHIT genes was restored in F6 cells. In addition, the morphology of F6 cells was altered, and the cell cycle was arrested in the G2 phase, with the initiation of apoptosis. Overall, the present findings demonstrated that the FHIT gene was methylated in F6 cells and demethylation treatment lead to changes in the biological characteristics, thereby promoting the apoptosis of F6 cells. FHIT gene methylation may be one of the molecular events involved in the development and transformation of FMSCs into F6 tumor cells.

View Figures

View References

1	Caplan AI: Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 213:341–347. 2007. View Article : Google Scholar : PubMed/NCBI
2	Xu H, Qian H, Zhu W, Zhang X, Yan Y, Mao F, Wang M, Xu H and Xu W: Mesenchymal stem cells relieve fibrosis of Schistosoma japonicum-induced mouse liver injury. Exp Biol Med (Maywood). 237:585–592. 2012. View Article : Google Scholar : PubMed/NCBI
3	Chen Y, Qian H, Zhu W, Zhang X, Yan Y, Ye S, Peng X, Li W and Xu W: Hepatocyte growth factor modification promotes the amelioration effects of human umbilical cord mesenchymal stem cells on rat acute kidney injury. Stem Cells Dev. 20:103–113. 2011. View Article : Google Scholar : PubMed/NCBI
4	Dayan V, Yannarelli G, Billia F, Filomeno P, Wang XH, Davies JE and Keating A: Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction. Basic Res Cardiol. 106:1299–1310. 2011. View Article : Google Scholar : PubMed/NCBI
5	Xu W, Qian H, Zhu W, Chen Y, Shao Q, Sun X, Hu J, Han C and Zhang X: A novel tumor cell line cloned from mutated human embryonic bone marrow mesenchymal stem cells. Oncol Rep. 12:501–508. 2004.PubMed/NCBI
6	Esteller M: CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. Oncogene. 21:5427–5440. 2002. View Article : Google Scholar : PubMed/NCBI
7	Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, et al: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 84:587–597. 1996. View Article : Google Scholar : PubMed/NCBI
8	Connolly DC, Greenspan DL, Wu R, Ren X, Dunn RL, Shah KV, Jones RW, Bosch FX, Muñoz N and Cho KR: Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res. 6:3505–3510. 2000.PubMed/NCBI
9	Guler G, Uner A, Guler N, Han SY, Iliopoulos D, McCue P and Huebner K: Concordant loss of fragile gene expression early in breast cancer development. Pathol Int. 55:471–478. 2005. View Article : Google Scholar : PubMed/NCBI
10	Jeong YJ, Jeong HY, Lee SM, Bong JG, Park SH and Oh HK: Promoter methylation status of the FHIT gene and Fhit expression: Association with HER2/neu status in breast cancer patients. Oncol Rep. 30:2270–2278. 2013.PubMed/NCBI
11	Sinha R, Hussain S, Mehrotra R, Kumar RS, Kumar K, Pande P, Doval DC, Basir SF and Bharadwaj M: Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: Indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population. PLoS One. 8:e601422013. View Article : Google Scholar : PubMed/NCBI
12	Zhang JF, Zhang JG, Kuai XL, Zhang H, Jiang W, Ding WF, Li ZL, Zhu HJ and Mao ZB: Reactivation of the homeotic tumor suppressor gene CDX2 by 5-aza-2′-deoxycytidine-induced demethylation inhibits cell proliferation and induces caspase-independent apoptosis in gastric cancer cells. Exp Ther Med. 5:735–741. 2013.PubMed/NCBI
13	Kang HF, Dai ZJ, Bai HP, Lu WF, Ma XB, Bao X, Lin S and Wang XJ: RUNX3 gene promoter demethylation by 5-Aza-CdR induces apoptosis in breast cancer MCF-7 cell line. Onco Targets Ther. 6:411–417. 2013.PubMed/NCBI
14	Lin J, Yao DM, Qian J, Wang YL, Han LX, Jiang YW, Fei X, Cen JN and Chen ZX: Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leuk Res. 32:1541–1545. 2008. View Article : Google Scholar : PubMed/NCBI
15	Cecener G, Tunca B, Egeli U, Bekar A, Tezcan G, Erturk E, Bayram N and Tolunay S: The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma. Cell Mol Neurobiol. 32:237–244. 2012. View Article : Google Scholar : PubMed/NCBI
16	Griffiths EA, Gore SD, Hooker CM, Mohammad HP, McDevitt MA, Smith BD, Karp JE, Herman JG and Carraway HE: Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics. 5:590–600. 2010. View Article : Google Scholar : PubMed/NCBI
17	Chen X, Zhang H, Li P, Yang Z, Qin L and Mo W: Gene expression of WWOX, FHIT and p73 in acute lymphoblastic leukemia. Oncol Lett. 6:963–969. 2013.PubMed/NCBI
18	Karahoca M and Momparler RL: Pharmacokinetic and pharmacodynamic analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics. 5:32013. View Article : Google Scholar : PubMed/NCBI
19	Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, Colombo MP, Gramegna M, Croce CM, et al: The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA. 96:8489–8492. 1999. View Article : Google Scholar : PubMed/NCBI
20	Alcazar O, Achberger S, Aldrich W, Hu Z, Negrotto S, Saunthararajah Y and Triozzi P: Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer. 131:18–29. 2012. View Article : Google Scholar : PubMed/NCBI
21	Xu X, Qian H, Zhu W, Zhang X, Yan Y, Wang M and Xu W: Isolation of cancer stem cells from transformed human mesenchymal stem cell line F6. J Mol Med Berl. 88:1181–1190. 2010. View Article : Google Scholar : PubMed/NCBI